Nvidia, Meta, More Lead Stock Rally As Shutdown Deal Advances — Positive
GOOG META Forbes — November 10, 2025American Airlines, United Airlines and Delta Airlines each traded up about 2% on Monday, following weeks of staffing disruptions at airports across the U.S. Transportation Secretary Sean Duffy warned last week that flight cancellations could rise to as high as 20% if the government shutdown continued to impact traffic control staffing, after Federal Aviation Administration administrator Bryan Bedford said up to 40% of controllers were not showing up for work on any given day. More than 5,000 flights were delayed and more than 1,000 were canceled across the U.S. on Saturday, with roughly one-third of flights at New York's LaGuardia …
Boeing stock dropped 13% after a $4.9 billion charge on the delayed 777X program, but long-term prospects remain positive. Q3 2025 results showed strong revenue growth and stabilization in defense, yet earnings missed due to the 777X setback. Despite near-term headwinds, BA is projected to recover margins, reduce debt, and generate significant cash by 2027.
Bristol Myers Gains 7.2% in a Month: Buy, Sell or Hold the Stock? — Positive
BMY Zacks Investment Research — November 10, 2025Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.
Ponce Financial (PDLB) is on the Move, Here's Why the Trend Could be Sustainable — Positive
PDLB Zacks Investment Research — November 10, 2025Ponce Financial (PDLB) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Despite Fast-paced Momentum, Controladora Vuela (VLRS) Is Still a Bargain Stock — Positive
VLRS Zacks Investment Research — November 10, 2025Controladora Vuela (VLRS) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Here's Why Momentum in Investar (ISTR) Should Keep going — Positive
ISTR Zacks Investment Research — November 10, 2025Investar (ISTR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Why Investors Need to Take Advantage of These 2 Industrial Products Stocks Now — Positive
CAT DE Zacks Investment Research — November 10, 2025Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Here's Why Momentum in Standard Motor Products (SMP) Should Keep going — Positive
SMP Zacks Investment Research — November 10, 2025Standard Motor Products (SMP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Jones Lang LaSalle (JLL) Is Attractively Priced Despite Fast-paced Momentum — Positive
JLL Zacks Investment Research — November 10, 2025Jones Lang LaSalle (JLL) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Camtek (CAMT) Surpasses Q3 Earnings and Revenue Estimates — Positive
CAMT Zacks Investment Research — November 10, 2025Camtek (CAMT) came out with quarterly earnings of $0.82 per share, beating the Zacks Consensus Estimate of $0.8 per share. This compares to earnings of $0.75 per share a year ago.
Despite Fast-paced Momentum, Ultra Clean (UCTT) Is Still a Bargain Stock — Positive
UCTT Zacks Investment Research — November 10, 2025Ultra Clean (UCTT) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Encore Capital Group (ECPG) Is Attractively Priced Despite Fast-paced Momentum — Positive
ECPG Zacks Investment Research — November 10, 2025If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Encore Capital Group (ECPG) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
These 2 Computer and Technology Stocks Could Beat Earnings: Why They Should Be on Your Radar — Positive
ADBE GRMN Zacks Investment Research — November 10, 2025Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why Investors Need to Take Advantage of These 2 Consumer Staples Stocks Now — Positive
LW OLLI Zacks Investment Research — November 10, 2025Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
These 2 Retail and Wholesale Stocks Could Beat Earnings: Why They Should Be on Your Radar — Positive
BBY URBN Zacks Investment Research — November 10, 2025Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Largest Real-World Study of Wearable Defibrillators Confirms Strong Effectiveness and Safety Performance of Kestra's ASSURE Device — Neutral
KMTS GlobeNewsWire — November 10, 2025KIRKLAND, Wash., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced primary results from the ASSURE® WCD Clinical Evaluation Post-Approval Study (ACE-PAS), presented as a late-breaking science session at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans. ACE-PAS, the largest prospective real-world study of wearable defibrillators to date, confirmed the strong safety and effectiveness of the ASSURE WCD in clinical practice.
NanoViricides receives approval to start Phase II clinical trial of NV-387 for MPox treatment in DRC — Positive
NNVC Proactive Investors — November 10, 2025NanoViricides (NYSE-A:NNVC) announced that it has received approval to begin its Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo (DRC). The clinical stage biotechnology company said the proposed Phase II clinical trial to evaluate safety and effectiveness of NV-387 for the treatment of patients with MPox disease caused by hMPXV infection is now cleared to proceed subject to filing of certain documents.
Freightcar America (RAIL) Q3 Earnings and Revenues Surpass Estimates — Positive
RAIL Zacks Investment Research — November 10, 2025Freightcar America (RAIL) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.08 per share a year ago.
The Trade Desk stock (NASDAQ: TTD) is down 6% in a single day, and has fallen a more significant 18% over the past month, despite the company reporting upbeat Q3 results and strong Q4 guidance.
Here is why we believe Accenture (ACN) stock warrants attention as a value investment. Currently, it is trading almost 37% lower than its high from the past year and at a PS multiple that falls below the average over the last 3 years.
